Abstracts tagged "predictors"

Abstract Number: 0875 • ACR Convergence 2021
Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity
Shivani Garg¹, Karen Hansen², Betty Chewning¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Despite weight-based dosing, hydroxychloroquine (HCQ) efficacy varies between individuals. Our meta-analysis based on several studies found that low HCQ levels increased risk of lupus…
Abstract Number: 1294 • ACR Convergence 2021
Predictors of BILAG-based Outcomes in Patients with SLE: Analysis from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort and MASTERPLANS Consortium
Trixy David¹, Li Su², Yafeng Cheng², Caroline Gordon³, Benjamin Parker¹, David Isenberg⁴, John A Reynolds⁵ and Ian N Bruce⁶, ¹The Kellgren Centre for Rheumatology, and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ²MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom, ³Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁴Centre for Rheumatology, University College London, London, United Kingdom, ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, and Rheumatology Department, City Hospital, Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom, ⁶The Kellgren Centre for Rheumatology; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, and Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Several novel SLE therapies are in development. Precision medicine aims to improve treatment practices and real-world outcomes. Certain factors, however, will likely reflect overall…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].